Weiss Ratings Reaffirms Sell (D-) Rating for Dyne Therapeutics (NASDAQ:DYN)

Key Points

• Weiss Ratings has reaffirmed a Sell (D-) rating for Dyne Therapeutics (NASDAQ:DYN), citing ongoing concerns about the company’s performance.
• Despite the negative outlook from Weiss Ratings, analysts from Royal Bank of Canada and Evercore ISI have set outperform ratings with target prices ranging from $23.00 to $30.00.
• Dyne Therapeutics' CEO, John Cox, recently purchased 100,000 shares of the company's stock, reflecting significant insider confidence in the firm's prospects.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report)'s stock had its "sell (d-)" rating reissued by stock analysts at Weiss Ratings in a report issued on Wednesday,Weiss Ratings reports.

DYN has been the topic of several other research reports. Royal Bank Of Canada reduced their target price on shares of Dyne Therapeutics from $25.00 to $23.00 and set an "outperform" rating on the stock in a report on Tuesday, July 29th. Evercore ISI reissued an "outperform" rating on shares of Dyne Therapeutics in a report on Friday, July 11th. JPMorgan Chase & Co. cut their target price on shares of Dyne Therapeutics from $10.00 to $9.00 and set a "neutral" rating on the stock in a research note on Tuesday, July 15th. Jones Trading initiated coverage on shares of Dyne Therapeutics in a research note on Thursday, June 26th. They set a "buy" rating and a $30.00 target price on the stock. Finally, Oppenheimer cut their target price on shares of Dyne Therapeutics from $34.00 to $13.00 and set an "outperform" rating on the stock in a research note on Wednesday, August 6th. Three equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Dyne Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $34.07.

Dyne Therapeutics Trading Up 4.4%

Shares of DYN stock traded up $0.61 on Wednesday, hitting $14.56. 3,004,364 shares of the company's stock traded hands, compared to its average volume of 2,508,558. The company has a debt-to-equity ratio of 0.17, a quick ratio of 16.83 and a current ratio of 16.83. Dyne Therapeutics has a one year low of $6.36 and a one year high of $35.90. The company's fifty day simple moving average is $12.66 and its 200 day simple moving average is $11.23. The stock has a market capitalization of $2.07 billion, a price-to-earnings ratio of -3.77 and a beta of 1.09.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last released its earnings results on Monday, July 28th. The company reported ($0.97) EPS for the quarter, beating the consensus estimate of ($0.99) by $0.02. Equities analysts forecast that Dyne Therapeutics will post -3.44 EPS for the current year.

Insider Transactions at Dyne Therapeutics

In other news, CEO John Cox bought 100,000 shares of the firm's stock in a transaction on Monday, July 14th. The stock was acquired at an average cost of $9.11 per share, with a total value of $911,000.00. Following the completion of the acquisition, the chief executive officer owned 242,179 shares of the company's stock, valued at approximately $2,206,250.69. This represents a 70.33% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 14.14% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Graham Capital Management L.P. purchased a new position in Dyne Therapeutics in the first quarter worth about $651,000. Rhumbline Advisers raised its holdings in Dyne Therapeutics by 4.2% in the first quarter. Rhumbline Advisers now owns 133,627 shares of the company's stock worth $1,398,000 after buying an additional 5,383 shares during the last quarter. Voleon Capital Management LP purchased a new position in Dyne Therapeutics in the first quarter worth about $624,000. GAMMA Investing LLC raised its holdings in shares of Dyne Therapeutics by 837.5% during the first quarter. GAMMA Investing LLC now owns 2,625 shares of the company's stock valued at $251,000 after purchasing an additional 2,345 shares during the last quarter. Finally, Swiss National Bank lifted its position in Dyne Therapeutics by 8.9% during the first quarter. Swiss National Bank now owns 118,300 shares of the company's stock valued at $1,237,000 after purchasing an additional 9,700 shares during the period. 96.68% of the stock is owned by hedge funds and other institutional investors.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.